

UNITED STATES SECURITIES AND EXCHANGE **COMMISSION**

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL				
OMB	3235-			
Number:	0104			
Estimated average				
burden hours pei	ſ			
response	0.5			

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)									
1. Name and Address of Reporting		2. Date of Event Requiring Statement (Month/Day/Year)		3. Issuer Name and Ticker or Trading Symbol					
Person *				NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]					
Tomblyn Michael	07/	/02/2015							
(Last) (First) (Mid	dle)	4. Relationship Person(s) to Iss		4. Relationship of Reporting			5. If Amendment, Date Original		
5600 BLAZER						Filed(Month/Day/Year)			
PARKWAY, SUITE 200				(Check all applicable) Director 10% Owner					
(Street)				X_ Officer (give Other (specify					
DUDI DI 011 42017			tit	le below) SVP_Ch	below) ief Med. Office	er		heck Applicable Line) filed by One Reporting Person	
DUBLIN, OH 43017				5 7 1 , CH	ici ivica. Oili			ed by More than One Reporting	
(City) (State) (7	:)		1.7.37	D			Person	0 1	
	ip)				ve Securiti	_			
1. Title of Security			mount of Se		3. Ownership			rect Beneficial	
(Instr. 4)		Beneficially Owned (Instr. 4)		nea	Form: Direct		vnership		
		(1112)			(D) or	(111011	,		
					Indirect (I)				
					(Instr. 5)				
Common Stock		100	$0,000\frac{(1)}{}$		D				
	no respon	class of securiti d to the colle and unless th	ection of in	formation	contained	in this		SEC 1473 (7-02)	
Table II - Derivative	Securities 1	Beneficially Ov	wned (<i>e.g.</i> , _]	puts, calls,	warrants, op	tions, c	onvertible	securities)	
1. Title of Derivative Security		ercisable and		d Amount o		5		6. Nature of Indirect	
(Instr. 4)	Expiration			Underlying	~		e Form of	Beneficial Ownership	
	(Month/Day/Y	ear)	Derivative Security		or Exercise			(Instr. 5)	
		I- · ·	(Instr. 4)		Price of Derivati		erivative ecurity:		
	Date Exercisable	Expiration		Amount or	a		Direct (D)		
	Excicisation	Date	Title	Number of			r Indirect		
				Shares		(1			
			~			(1	(nstr. 5)		
Stock Option (Right to Buy)	<u>(2)</u>	01/01/2025	Common Stock	100,000	\$ 1.89		D		
Donouting Owner	8								
Reporting Owner	8								
Relationships									
Reporting Owner Name / Addre	Director				Other				
Tomblyn Michael									
5600 BLAZER PARKWAY			CVD CL:	CM 1 0	cc				

SVP, Chief Med. Officer

Signatures

DUBLIN, OH 43017

SUITE 200

William J. Kelly, attorney-in-fact	07/20/2015
------------------------------------	------------

**Signature of Reporting Person	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant of restricted stock on 3/3/2015, vesting 25% per year beginning on first anniversary of award date.
- (2) Option vests 25% per year beginning on the first anniversary of date options were awarded (1/1/15).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Brent L. Larson and William J. Kelly, signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Navidea Biopharmaceuticals, Inc. (the "Company"), a Form ID, Forms 3, 4, and 5 and any other documents necessary to facilitate the filing of reports in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID or Forms 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13th day of July, 2015.

Signature: /s/ Michael Tomblyn, MD Print Name: Michael Tomblyn, MD